Registered title, quoted from ClinicalTrials.gov
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteChangzhou No.2 People's Hospital常州市第二人民医院ChangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07719556, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically confirmed diagnosis of mantle cell lymphoma (MCL) and treatment-naïve;
Inclusion criterion 5
All patients of childbearing potential must agree to use effective contraceptive measures during the study and for 24 months after study treatment discontinuation. Female patients of childbearing potential must have a negative urine pregnancy test prior to the first dose of study treatment.
Inclusion criterion 11
Received prior treatment for lymphoma within 2 weeks before study enrollment;
Exclusion criterion 1
Known active bacterial, viral, fungal, or other infection (excluding fungal infection of the nail bed), or major infection within 2 weeks prior to the first dose of study drug;
Exclusion criterion 7
Hepatic function: AST (SGOT) and ALT (SGPT) ≤ 2.5 × upper limit of normal (ULN) (in the absence of liver involvement) or ≤ 5 × ULN (in the presence of liver involvement); total bilirubin (TBIL) ≤ ULN; serum creatinine (CRE) ≤ 1.5 × ULN;
Inclusion criterion 8
Creatinine clearance ≥ 30 mL/min, calculated using the Cockcroft-Gault formula;
Inclusion criterion 9
Known active hepatitis C virus (HCV) infection; or other acquired or congenital immunodeficiency disorders, including but not limited to human immunodeficiency virus (HIV) infection;
Exclusion criterion 9
Pregnant or breastfeeding women;
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07719556, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily participate and sign the informed consent form;
- Age ≥ 18 years, male or female;
- Life expectancy ≥ 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Patients with ECOG 3 may be enrolled only if the decline in performance status is attributed to the underlying disease and the investigator determines that they may benefit from the treatment;
- Pathologically confirmed diagnosis of mantle cell lymphoma (MCL) and treatment-naïve;
- Presence of measurable and/or evaluable lymphoma lesions;
- Adequate bone marrow reserve, defined as: absolute neutrophil count > 1.0×10⁹/L or platelet count > 75×10⁹/L, unless cytopenias are considered to be related to bone marrow involvement by lymphoma and deemed recoverable by the investigator;
- Hepatic function: AST (SGOT) and ALT (SGPT) ≤ 2.5 × upper limit of normal (ULN) (in the absence of liver involvement) or ≤ 5 × ULN (in the presence of liver involvement); total bilirubin (TBIL) ≤ ULN; serum creatinine (CRE) ≤ 1.5 × ULN;
- Creatinine clearance ≥ 30 mL/min, calculated using the Cockcroft-Gault formula;
- Able to comply with the study visit schedule and other protocol requirements;
- All patients of childbearing potential must agree to use effective contraceptive measures during the study and for 24 months after study treatment discontinuation. Female patients of childbearing potential must have a negative urine pregnancy test prior to the first dose of study treatment.
Exclusion Criteria:
- Received prior treatment for lymphoma within 2 weeks before study enrollment;
- Any serious medical condition, including but not limited to:
- Uncontrolled hypertension (defined as blood pressure that remains uncontrolled after at least 4 weeks of treatment with a reasonable and tolerable regimen of 3 or more antihypertensive agents [including diuretics] at adequate doses, or requiring 4 or more antihypertensive agents to achieve adequate control);
- Uncontrolled congestive heart failure within 6 months prior to screening (New York Heart Association [NYHA] Class III [moderate] or Class IV [severe] cardiac disease);
- Left ventricular ejection fraction (LVEF) < 50%;
- Symptomatic coronary artery disease (e.g., chest tightness, chest pain, palpitations, fatigue) or coronary artery disease requiring medical therapy; ⑤Severe bradycardia (heart rate < 40 beats per minute [bpm]) with hypotension, dizziness, or syncope; patients with a history of arrhythmia should undergo cardiac evaluation;
- Known active bacterial, viral, fungal, or other infection (excluding fungal infection of the nail bed), or major infection within 2 weeks prior to the first dose of study drug;
- Moderate to severe hepatic impairment (Child-Pugh Class B or C); ⑧Active bleeding within 2 months prior to screening, or clear evidence of bleeding diathesis as judged by the investigator; ⑨Current pulmonary disease that impairs lung function, such as pulmonary fibrosis or drug-related pneumonitis, which is deemed intolerable by the investigator; ⑩Any psychiatric or cognitive disorder that may limit the patient's ability to understand, execute, or comply with the informed consent and study requirements;
- Known active hepatitis C virus (HCV) infection; or other acquired or congenital immunodeficiency disorders, including but not limited to human immunodeficiency virus (HIV) infection;
- All patients with central nervous system (CNS) involvement by lymphoma;
- Diagnosis of or receiving treatment for another malignancy other than lymphoma, except for the following:
①Malignancy that has been treated with curative intent and with no known active disease for ≥ 5 years prior to enrollment;
②Adequately treated basal cell carcinoma of the skin (excluding melanoma) with no evidence of disease;
③Adequately treated carcinoma in situ of the cervix with no evidence of disease;
- Known hypersensitivity to any study drug;
- Pregnant or breastfeeding women;
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment;
- Requirement for anticoagulation therapy with warfarin or equivalent vitamin K antagonists;
- Requirement for long-term treatment with strong cytochrome P450 3A (CYP3A) inhibitors;
- Receipt of live attenuated vaccine within 4 weeks prior to enrollment.
Quoted from ClinicalTrials.gov, NCT07719556, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07719556, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.